Savara (SVRA) Revenue (2013 - 2020)

Savara (SVRA) posted quarterly Revenue of $1000.0 for Q4 2020, down 99.61% quarter-over-quarter from $256000.0 in Q3 2020.

Analysis

Savara (SVRA) Revenue (2013 - 2020) Analysis & Trends

Savara (SVRA) has reported Revenue for 5 consecutive years, with $1000.0 the latest figure, recorded in Q4 2020.

In Q4 2020, Revenue changed N/A year-over-year to $1000.0; the TTM figure through Mar 2022 stood at $1000.0 (changed N/A YoY), while the FY2020 annual figure was $257000.0, changed N/A from the prior year.
Revenue slipped to $1000.0 in Q4 2020 per SVRA's latest filing, from $256000.0 in the prior quarter.
Across five years, Revenue topped out at $400000.0 in Q4 2016 and bottomed at -$94000.0 in Q2 2017.
Historically, Revenue has averaged $117000.0 across 3 years, with a median of $69500.0 in 2016.
On a YoY basis, Revenue climbed as much as 640.74% in 2016 and fell as far as 640.74% in 2016.
Savara's Revenue stood at $400000.0 in 2016, then tumbled by 123.5% to -$94000.0 in 2017, then surged by 101.06% to $1000.0 in 2020.
Business Quant data shows SVRA's Revenue at $1000.0 in Q4 2020, $256000.0 in Q3 2020, and -$94000.0 in Q2 2017.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	86.04 Bn	78.05 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	63.70 Bn	58.52 Bn	1.37 Bn	1.52 Bn
4	Moderna	57.56 Bn	52.42 Bn	52.00 Mn	145.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	-
6	BeOne Medicines	40.16 Bn	35.06 Bn	1.53 Bn	1.71 Bn
7	Alnylam Pharmaceuticals	35.63 Bn	32.32 Bn	992.69 Mn	1.29 Bn
8	Royalty Pharma	28.63 Bn	27.79 Bn	-	674.14 Mn
9	Insmed	27.73 Bn	26.57 Bn	358.27 Mn	425.49 Mn
10	Savara	1.35 Bn	1.35 Bn	-	-

Historic Data

Download Data